Monthly Archives: December 2012

Arizona Pain Specialists, the leading pain clinics in Phoenix and Scottsdale metropolitan areas, are now offering cutting edge platelet rich plasma injections. Also known as PRP for short, the regenerative medicine injections work well for relieving pain by recruiting the body's stem cells to repair the damaged area.

Phoenix, AZ (PRWEB) December 19, 2012

Regenerative medicine with PRP represents the current state of the art treatment in pain management. Most treatments up until recently have been good at pain relief by masking the problem, rather than repairing it. While these treatments, such as cortisone injections, are excellent at short term pain relief, they are not fixing the actual problem.

Platelet rich plasma actually provides growth factors which have the potential to regenerate damaged cartilage, tendons and ligament. The treatment consists of using the patient's own blood from a simple blood draw, and centrifuging the specimen to obtain the platelets and growth factors in the plasma.

The PRP injection has shown significant benefit in initial studies, including a review by Sampson et al from a 2008 Current Review Musculoskeletal Medicine study. The injections are beneficial for tendinitis of the elbow, shoulder, hip, knee and ankle. Reviews are also showing benefit for arthritis as well.

Regenerative medicine with PRP represents the cutting edge in modern medicine for musculoskeletal conditions. It represents a different approach to treating painful conditions, and Arizona Pain takes pride in offering the latest therapies while taking care to preserve patient safety.

The Board Certified and Fellowship Trained doctors at Arizona Pain Specialists offer platelet rich plasma injections as an outpatient treatment. Phoenix pain management services are available across the valley serving Glendale, Scottsdale, Chandler, Mesa, Surprise, Tempe, Goodyear and more.

More information and scheduling is available at (602) 507-6550.

Jennifer Arizona Pain Specialists (602) 507-6550 Email Information

Original post:
Best Pain Clinics in AZ, Arizona Pain Specialists, Now Offering Regenerative Medicine with Platelet Rich Plasma ...

ALAMEDA, Calif.--(BUSINESS WIRE)--

BioTime, Inc. (NYSE MKT: BTX) today announced the appointment of Jeffrey Janus as its Vice President of Sales and Marketing. Mr. Janus primary focus will be to create, market, and sell research products for BioTime and its subsidiaries in the expanding field of regenerative medicine. Mr. Janus has more than 25 years of experience and a proven track record of creating profitable commercial cell-based business.

Jeffrey brings tremendous expertise in regenerative medicine, developing and selling research products and reagents, and building business units, said Michael D. West, PhD, BioTimes Chief Executive Officer. We welcome Jeffrey to the BioTime team and look forward to working together with him in expanding our development, marketing, and sale of research products.

I am honored and excited to be a part of the BioTime team. It is especially gratifying to be working with BioTimes partner LifeMap Sciences, Inc. and their unique and powerful on-line integrated database suite for genomic, biomedical and stem cell research. This in-depth database suite, linked to BioTimes unique PureStem lines of standardized human progenitor cells, gives researchers a comprehensive set of tools to study human embryonic development and stem cell biology. Medical research has always depended upon the availability of standardized research products and information, and BioTime and LifeMap have become leaders in consolidating biomedical information with standardized stem cells.

Mr. Janus was most recently Senior Vice President of Operations at International Stem Cell Corporation (ISCO), where he led the company to discover a process known as parthenogenesis resulting in functional human pluripotent stem cells without the use of fertilized human embryos, and was previously the CEO and founder of Lifeline Cell Technology, LLC, a subsidiary of ISCO. Prior to that, he was a member of the founding team that created Clonetics Corporation and the Clonetics brand of primary human cell products. In addition to his extensive experience in developing and selling cell-based products to the research market, Mr. Janus has led teams of scientists both internally and through external domestic and international collaborations with major academic institutions to conduct research. He has grown several biotechnology companies from the ground up, from licensing or patenting intellectual property, to building teams to develop, manufacture and market products profitably. He has a deep understanding of the process of creating and managing teams and has used the strategic planning process to great success.

Mr. Janus has a Masters Degree in Business Administration from California State University, San Diego and a Bachelor Degree in Biochemistry from the University of California at Davis and is a published author of breakthrough papers in the field of parthenogenesis and stem cell research.

About BioTime, Inc.

BioTime, headquartered in Alameda, Calif., is a biotechnology company focused on regenerative medicine and blood plasma volume expanders. Its broad platform of stem cell technologies is enhanced through subsidiaries focused on specific fields of application. BioTime develops and markets research products in the fields of stem cells and regenerative medicine, including a wide array of proprietary PureStem cell lines, HyStem hydrogels, culture media, and differentiation kits. BioTime is developing Renevia (formerly known as HyStem-Rx), a biocompatible, implantable hyaluronan and collagen-based matrix for cell delivery in human clinical applications. BioTime's therapeutic product development strategy is pursued through subsidiaries that focus on specific organ systems and related diseases for which there is a high unmet medical need. BioTime's majority owned subsidiary Cell Cure Neurosciences Ltd. is developing therapeutic products derived from stem cells for the treatment of retinal and neural degenerative diseases. BioTime's subsidiary OrthoCyte Corporation is developing therapeutic applications of stem cells to treat orthopedic diseases and injuries. Another subsidiary, OncoCyte Corporation, focuses on the diagnostic and therapeutic applications of stem cell technology in cancer, including the diagnostic product PanC-Dx currently being developed for the detection of cancer in blood samples. ReCyte Therapeutics, Inc. is developing applications of BioTime's proprietary induced pluripotent stem cell technology to reverse the developmental aging of human cells to treat cardiovascular and blood cell diseases. BioTime's subsidiary LifeMap Sciences, Inc., markets GeneCards, the leading human gene database, and has developed an integrated database suite to complement GeneCards that includes the LifeMap Discovery database of embryonic development, stem cell research and regenerative medicine, and MalaCards, the human disease database. LifeMap is also marketing BioTime research products. BioTime's lead product, Hextend, is a blood plasma volume expander manufactured and distributed in the U.S. by Hospira, Inc., and in South Korea by CJ CheilJedang Corporation under exclusive licensing agreements. Additional information about BioTime can be found on the web at http://www.biotimeinc.com.

Forward-Looking Statements

Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for BioTime and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of BioTime and its subsidiaries, particularly those mentioned in the cautionary statements found in BioTime's Securities and Exchange Commission filings. BioTime disclaims any intent or obligation to update these forward-looking statements.

Original post:
BioTime Announces the Appointment of Jeffrey Janus as Vice President

MARLBOROUGH, Mass.--(BUSINESS WIRE)--

Advanced Cell Technology, Inc. (ACT; OTCBB: ACTC or the Company), a leader in the field of regenerative medicine, today announced that its iPS cell-derived human platelet program has been named as one of the 10 Ideas That Will Shape The Year in the Christmas and New Year Special issue of the New Scientist, widely considered to be one of the most influential science and technology news magazines in the world.

The list includes innovations in different scientific areas such as health and medicine, climate change, technology and others. ACTs platelet program aims to provide a renewable, donorless source of blood platelets to people in need of platelet transfusions.

Human iPS cells are a game-changer in medicine, said Robert Lanza, M.D., chief scientific officer of ACT. They offer the possibility to generate a non-controversial, unlimited source of patient-specific stem cells without embryo destruction. Owing to their short storage time, there is a constant demand for this life-saving blood component. Since platelets dont contain any genetic material, they cannot form tumors, which makes them ideal for the first clinical trial involving the iPS cell technology. We hope to initiate the first clinical trial using these promising cells in 2013.

ACT plans to compare normal and iPS cell-derived platelets in eight healthy volunteers and analyze recovery and survival. Additionally, normal platelets will be compared to human embryonic stem cell-derived platelet cells.

We appreciate this recognition from the New Scientist, commended Gary Rabin, chairman and CEO. It speaks to the growing importance of the stem cell and regenerative medicine sector.

Link to Article in New Scientist: http://www.newscientist.com/article/mg21628965.400-2013-smart-guide-revolutionary-human-stem-cell-trial.html

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc., is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit http://www.advancedcell.com.

Forward-Looking Statements

See more here:
New Scientist Magazine Selects ACT’s Induced Pluripotent Stem (iPS) Cell-Derived Human Platelet Program As One of ‘10 ...